Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information, please visit www.ocugen.com.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Brimonidine 0.18% Nanoemulsion
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):